Oxolife is the female fertility biotech based in Barcelona, focused on the development of a promising first-in class drug for female fertility, in a specific field were none has been effective to date, enhancing embryo implantation to increase Live Birth Rates.Infertility affects 76 M women worldwide. No treatment has yet been developed that addresses implantation process, accounting for more than 50% of pregnancies lost in IVF.These remain unsolved problems in the reprodutive health and women's health. OXO-001 is a first-in-class oral non-hormonal drug for the treatment of infertile women that increases embryo implantation and pregnancy rates.